Precigen, Inc.
PGEN
NASDAQ·Healthcare·Biotechnology·Mkt cap $2.5B
$7.10
▼ -0.56%
P/E
-6.09
Mkt Cap
$2.5B
52-Wk Range
$2.99–$7.72
52-Week Range
$2.99 - $7.72
P/E
Fwd P/E
Beta
Div Yield
Avg Vol
Shares Out
Mkt Cap
Price action
Price chart
Up 70.7% over the trailing year
Total returns
Price performance
Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.
Why we rate it this way
The thesis at a glance
Bull and bear case · plain-English context across the five lenses we evaluate.
Bull Case
6 reasons
- Proprietary UltraVector platform for complex gene expression programming
- Multiple non-viral and viral delivery technologies (Sleeping Beauty, AdenoVerse, L. lactis)
- UltraCAR-T platform with enhanced immune cell engineering capabilities
- Inducible gene switch systems (RhoSwitch) enabling precise therapeutic control
- Genetically engineered swine technology for regenerative medicine applications
- Extensive patent portfolio and strategic collaborations with established biotech partners
Bear Case
2 risks
- Average volatility.
- Growth premium of 2.3x vs Biotech & Therapeutics peers. Elevated but may be justified by growth trajectory.
Growth
Turning profitable
Expansion of UltraCAR-T clinical programs in oncology indications
Value
Growth premium of 2.3x vs Biotech & Therapeutics peers. Elevated but may be justified by growth trajectory.
Momentum
Hot
+98.9% over 3m
Quality
Excellent
Emerging growth company (500% revenue growth). Early stage with higher risk.
Dividend
None
No dividend
Smart-money signal
Who's buying PGEN right now
Insider Form 4s, 13F institutional filings, and Congressional disclosures - at a glance.
Earnings track record
Latest print - beat on both lines
AI-summarized recap of last quarter, plus the surprise on every print.
Next: Nov 12, 2026
AUG 4, 2026
Reported EPS of $0.05 vs -$0.01 consensus (+514.3% surprise). Revenue of $55.0M vs $28.0M expected (+96.5%). Beat on both top and bottom lines.
EPS surprise · last 4Q
1 of 1 beats
Estimate
Actual
Q3 26
+514.3%
Revenue trend · last 8Q
—
-3%
+26%
+19%
+207%
+284%
+1634%
0%
Q3 24
Q4 24
Q1 25
Q2 25
Q3 25
Q4 25
Q1 26
Q2 26
$953.0K
$1.2M
$1.3M
$856.0K
$2.9M
$4.6M
$23.3M
$856.0K
Margins · last 8Q
Gross
0.0%
Profit
-3112.4%
Wall Street consensus
2 analysts · 100% Buy
Live ratings and price targets aggregated across covering analysts.
Buy
100%
Hold
0%
Sell
0%
Median Price Target
—
Latest: HC Wainwright · Aug 5, 2026
vs Industry
How PGEN stacks vs Biotechnology
Stock metrics vs industry averages. Green = better than industry.
Industry comparison data unavailable for this stock.
Related